dcsimg Aranesp® (darbepoetin alfa) – Transfusion Benefits and Risks
› Email› Print

Transfusions have potential benefits and risks1-3

  • According to the National Kidney Foundation KDOQI, despite use of pharmacologic agents for the treatment of anemia, blood transfusions are occasionally required, particularly in the setting of acute bleeding.4
  • RBC transfusions should be used judiciously in patients with CKD, especially because of the potential development of sensitivity affecting future kidney transplant.4
Transfusions have potential benefits and risks

Reducing the risk of alloimmunizations and/or other
RBC transfusion-related risks is a goal for patients with CKD.5

Limitations of Use

  • Aranesp® has not been shown to improve quality of life, fatigue, or patient well-being.
  • Aranesp® is not indicated for use as a substitute for red blood cell transfusions in patients who require immediate correction of anemia.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
CKD = chronic kidney disease; KDOQI = National Kidney Foundation Kidney Disease Outcomes Quality Initiative; RBC = red blood cell.
References: 1. Dzieczkowski JS, Anderson KC. Transfusion biology and therapy. In: Fauci AS, Kasper DL, Longo DL, et al, eds. Harrison’s Principles of Internal Medicine. 17th ed. New York, NY: McGraw-Hill; 2008:707-713. 2. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol. 2007;14:682-687. 3. United States Renal Data System. 2004 Annual Data Report. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2004. 4. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis. 2006;47:S1-S146. 5. Aranesp® (darbepoetin alfa) prescribing information, Amgen.

Biotechnology by Amgen®